Ayça Burcu Kahraman

Ayça Burcu Kahraman

Auto-generated profile, based on publicly available information

Ayça Burcu Kahraman

Division of Pediatric Metabolism, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2021 in Journal of Pediatric Endocrinology and Metabolism
Verified
Journal Article
Closed access
AKAyça Burcu Kahraman
Ayça Burcu Kahraman
YYYILMAZ YILDIZ
YILMAZ YILDIZ
KÇKısmet Çıkı
Kısmet Çıkı
HAHalil Tuna Akar
Halil Tuna Akar
IEİzzet Erdal
İzzet Erdal
HSHatice Serap Sivri
Hatice Serap Sivri
Objectives Lysosomal storage diseases (LSD) constitute an important group of metabolic diseases, consisting of approximately 60 disorders. In some types of lysosomal diseases, enzyme replacement therapy (ERT) is administered intravenously in weekly or biweekly doses. Unfortunately, scheduled ERT during COVID-19 was disrupted. We considered the possibility of adverse outcomes caused by the disruption in the treatment of patients with lysosomal storage disorders. Methods During the COVID-19 pandemic, we conducted a questionnaire that was delivered via Internet to assess how this vulnerable patient group was affected by the pandemic in terms of their access to treatment and their disease-related symptoms. Results The questionnaire was filled out by 75 patients. There were 35 patients whose treatment dose was missed because of COVID-19. The most common reason for skipping treatment was not wanting to go to the hospital for fear of contracting COVID-19. These 35 patients missed a median of four doses of ERT (range: 1–16 dosages). Twenty-one patients (60%) claimed that they were affected physically by not taking ERT (20 mucopolysaccaridoses, 1 Fabry disease), whereas 14 (40%) did not. Conclusions Interruption of ERT during the COVID-19 pandemic may have significant consequences. It may be beneficial to switch to home treatment or reserve dedicated facilities. With proper planning and management, the treatment disruptions of this particular group can be avoided.

15 May 2025 in Postgraduate Medicine
Verified
Journal Article
Closed access
İEİzzet Erdal
İzzet Erdal
AKAyça Burcu Kahraman
Ayça Burcu Kahraman
YYYILMAZ YILDIZ
YILMAZ YILDIZ
SYSıddika Songül Yalçın
Sıddika Songül Yalçın
Newborn screening and childhood immunization are among the most successful public health initiatives. Turkey has a high vaccination coverage (95-99%), but a recent decline is concerning. Vaccine hesitancy (VH) is a growing global issue, identified by the WHO as a major public health threat. Given that VH may correlate with attitudes toward other health practices, we explored whether early engagement with the health system via newborn screening influences childhood vaccine acceptance. Although these programs are implemented separately but concurrently as part of the national healthcare system in Turkey, integrating newborn screening and immunization initiatives may increase vaccine uptake through early engagement and trust building. This study aims to evaluate the relationship between newborn screening and parental vaccine hesitancy. This study was conducted at a tertiary care center in Turkey from July 2023 to April 2024. Parental VH was assessed using the PACV scale, along with questions on demographics and parental vaccination status. Participants with PACV score ≥ 50 were classified as VH+, others as VH-. Groups were compared using t-tests, Mann - Whitney U, chi-squared, or Fisher's exact tests. Multiple logistic regression was used to analyze related factors. This analytic descriptive study included 481 parents (125 with children diagnosed with biotinidase deficiency or PKU via newborn screening, and 356 with healthy children aged 2-6). The mean age of respondents was 35 years, and the majority were mothers with a college education. The main sources of vaccine information were health professionals, followed by social media and family. Overall, 19.8% of parents were vaccine-hesitant, with a lower rate in the patient group (12% vs. 22.5%). VH was higher in fathers with chronic diseases (35.1% vs 18.1%, p = .012) and was lower in mothers received tetanus vaccine during pregnancy (16.1% vs. 30.6%, p = .001) or parents who received COVID-19 vaccine (mothers: 13.9% vs. 50.6%, fathers: 14.8% vs. 49.2%, both p < .001). VH was lower in those consulting healthcare professionals and higher in those relying on social media or non-medical sources. Diagnosis and treatment through newborn screening had an effect of 0.47 odds on VH in the overall group (95% CI = 0.24-0.92, p = .028). This study found lower vaccine hesitancy among participants in newborn screening programs and those whose parents received adult vaccinations, potentially due to increased contact with health professionals and greater health-seeking behavior. The influence of social media on vaccine hesitancy, evident in the general population, was not observed among cases, suggesting that systematic follow-up may buffer against external risk factors. Studies with matched cohorts, real-time data collection, and anonymous surveys are needed to improve generalizability, support causal inference, and reduce biases.

26 June 2022 in Neuromuscular Disorders
Verified
Journal Article
Closed access
AKAyca Burcu Kahraman
Ayca Burcu Kahraman
BKBekir Karakaya
Bekir Karakaya
YYYılmaz Yıldız
Yılmaz Yıldız
SKSaygin Kamaci
Saygin Kamaci
SKSelman Kesici
Selman Kesici
GHGoknur Haliloglu
Goknur Haliloglu

31 May 2025 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
EKEngin Köse
Engin Köse
IIInci Inci
Inci Inci
HYHAVVA YAZICI
HAVVA YAZICI
TZTanyel Zubarioglu
Tanyel Zubarioglu
SKSebile Kılavuz
Sebile Kılavuz
FEFatma Tuba Eminoğlu
Fatma Tuba Eminoğlu
Long-chain fatty acid oxidation disorders (LC-FAOD) are a rare metabolic condition that results in impaired fatty acid utilization, leading to metabolic crises, hospitalization, and reduced quality of life. Despite dietary management, many patients experience ongoing complications. Triheptanoin, a seven-carbon triglyceride, has emerged as a therapeutic alternative by providing an energy source and supporting metabolic stability. This study aims to evaluate the clinical outcomes of LC-FAOD patients receiving triheptanoin therapy in Türkiye. A retrospective nationwide study was conducted to analyze 14 patients with LC-FAOD who received oral triheptanoin as part of a compassionate use program in Türkiye. The study collected data on emergency department visits, hospitalizations, metabolic decompensation episodes, creatine kinase (CK) levels, hypoglycemia, and cardiac function. Additionally, patient-reported outcomes were assessed through surveys. The findings of the study demonstrated that triheptanoin treatment led to a significant reduction in the number of emergency service applications and hospitalizations per month (p < 0.01). A notable decrease in the frequency of myalgia attacks was observed, while the decline in rhabdomyolysis episodes did not reach statistical significance. Furthermore, creatine kinase levels during metabolic crises exhibited a substantial decrease following triheptanoin therapy (p < 0.0001).Among patients with cardiomyopathy, cardiac function showed improvement in four out of seven patients. Survey data indicated an improvement in appetite, physical performance, and overall quality of life. Conclusion: Triheptanoin treatment has been demonstrated to be associated with significant clinical improvements in patients diagnosed with LC-FAOD, including a reduction in the frequency of emergency department visits, hospitalizations, and metabolic crises. These findings provide support for the utilization of triheptanoin as a therapeutic approach that holds promise in the management of LC-FAOD. What is Known: • Long-chain fatty acid oxidation disorders (LC-FAOD) are associated with significant morbidity due to metabolic crises, despite conventional dietary treatment including medium-chain triglycerides (MCT). What is New: • This nationwide study demonstrates that triheptanoin therapy significantly reduces emergency visits, hospitalizations, and creatine kinase levels during crises, and improves patient-reported outcomes, including physical activity and quality of life, in LC-FAOD patients in Türkiye.

4 January 2022 in Molecular Syndromology
Verified
Journal Article
Open access
PDF file
AKAyca Burcu Kahraman
Ayca Burcu Kahraman
HAHalil Tuna Akar
Halil Tuna Akar
NLNaz Güleray Lafcı
Naz Güleray Lafcı
YYYILMAZ YILDIZ
YILMAZ YILDIZ
ATAyşegül Tokatlı
Ayşegül Tokatlı
Tyrosinemia type III is an extremely rare autosomal recessive disease, with only 19 patients yet reported. It is caused by a deficiency of the 4-hydroxyphenylpyruvate dioxygenase enzyme, resulting from biallelic mutations in the HPD gene. Although the clinical spectrum of the disease is not fully known, most patients present with neurodevelopmental symptoms. We report on a 20-month-old patient who was investigated due to developmental delay and dysmorphic features. The girl had a novel splice-site mutation in the HPD gene and ventriculomegaly in cranial imaging, which was not previously associated with tyrosinemia type III. Our patient had mild subjective improvement in social skills and language development after dietary therapy was started and her tyrosine levels decreased. We also summarize clinical, biochemical, and genetic findings of previously published patients with biallelic HPD mutations.

9 September 2022 in Balkan Medical Journal
Verified
Journal Article
Open access
HAHalil Tuna Akar
Halil Tuna Akar
YYYILMAZ YILDIZ
YILMAZ YILDIZ
GGGökhan Güvenkaya
Gökhan Güvenkaya
KÇKısmet Çıkı
Kısmet Çıkı
AKAyça Burcu Kahraman
Ayça Burcu Kahraman
ATAyşegül Tokatlı
Ayşegül Tokatlı
Background: GM1 gangliosidosis is an autosomal recessive lysosomal storage disease caused by biallelic mutations in the GLB1 gene. Neurodegeneration, hypotonia, visceromegaly, macular cherry -red spots, skeletal dysplasia, and coarse and dysmorphic face are the major clinical features. Aims: To evaluate the demographic and clinical data of patients with GM1 gangliosidosis in a single center. Study Design: A retrospective clinical study. Methods: This study included patients followed at Hacettepe University Ihsan Dogramaci Children's Hospital Pediatric Metabolism Unit with the diagnosis of GM1 gangliosidosis between 1988 and 2021. Hospital records of the patients were reviewed for demographic, clinical, and laboratory findings. Results: Fourteen patients were included in the study and 10 (71.4%) were male. The age at onset of clinical symptoms was between 0 and 5 months, and the median time to diagnosis after the first symptom was 4.3 (0-13) months. Motor delay (54%) was the most common initial symptom. The median follow-up period was 14.8 (0.4-92.2) months. Twelve patients (85.7%) died, and all deaths occurred before the age of 24 months. The median survival was 21.3 (95% confidence interval, 15.5-24.9) months. Higher leukocyte beta-galactosidase activity correlated with later age at onset (p = 0.575), later age at diagnosis (p = 0.618), and longer diagnostic delay (p = 0.702) (p < 0.05). Conclusion: Median survival in patients with GM1 gangliosidosis is less than 24 months. Beta-galactosidase enzyme activity may be associated with clinical onset and time of diagnosis in these patients.